Table 1.
Visits and Treatments in Years 3 to 5 by Randomized Treatment Group
| Visits and treatments in the study eye | All | Aflibercept | Bevacizumab | Ranibizumab |
|---|---|---|---|---|
| N | 317 | 115 | 96 | 106 |
| Visits in years 3 to 5, median (IQR) | 12 (5, 21) | 12 (5, 21) | 13 (7, 20) | 12 (5, 21) |
| Visits by year, median (IQR) | ||||
| Year 3 | 4 (2, 7) | 4 (1, 7) | 4 (2, 8) | 3 (1, 8) |
| Year 4 | 4 (1, 7) | 4 (1, 7) | 4 (2, 7) | 4 (1, 7) |
| Year 5 | 4 (1, 7) | 4 (1, 7) | 3 (1, 7) | 4 (1, 7) |
| Any treatments in years 3 to 5 for | ||||
| Diabetic macular edema, N (%) | 208 (66%) | 80 (70%) | 62 (65%) | 66 (62%) |
| Diabetic retinopathy, N (%) | 62 (20%) | 25 (22%) | 15 (16%) | 22 (21%) |
| DME or DR, N (%) | 221 (70%) | 83 (72%) | 65 (68%) | 73 (69%) |
| Any anti-VEGF injections in years 3 to 5, N (%) | 217 (68%) | 81 (70%) | 65 (68%) | 71 (67%) |
| Anti-VEGF injections in years 3 to 5 | ||||
| Mean (SD) | 6.7 (7.5) | 7.1 (7.5) | 6.5 (7.8) | 6.5 (7.3) |
| Median (IQR) | 4 (0, 12) | 4 (0, 13) | 2 (0, 13) | 4 (0, 11) |
| Anti-VEGF injections by year, median (IQR) | ||||
| Year 3 | 1 (0, 4) | 1 (0, 4) | 1 (0, 4) | 1 (0, 3) |
| Year 4 | 1 (0, 4) | 1 (0, 4) | 0 (0, 3) | 1 (0, 4) |
| Year 5 | 0 (0, 4) | 1 (0, 4) | 0 (0, 3) | 0 (0, 4) |
| Anti-VEGF treatment in years 3 to 5, N (%) | ||||
| None | 100 (32%) | 34 (30%) | 31 (32%) | 35 (33%) |
| Aflibercept only | 70 (22%) | 36 (31%) | 21 (22%) | 13 (12%) |
| Bevacizumab only | 56 (18%) | 19 (17%) | 18 (19%) | 19 (18%) |
| Ranibizumab only | 31 (10%) | 7 (6%) | 11 (11%) | 13 (12%) |
| More than one drug | 60 (19%) | 19 (17%) | 15 (16%) | 26 (25%) |
| Aflibercept injections in years 3 to 5, median (IQR) | 0 (0, 6) | 0 (0, 8) | 0 (0, 4) | 0 (0, 6) |
| Bevacizumab injections in years 3 to 5, median (IQR) | 0 (0, 2) | 0 (0, 2) | 0 (0, 1) | 0 (0, 2) |
| Ranibizumab injections in years 3 to 5, median (IQR) | 0 (0, 0) | 0 (0, 0) | 0 (0, 0) | 0 (0, 1) |
| Any Corticosteroid injections in years 3 to 5, N (%) | 32 (10%) | 12 (10%) | 13 (14%) | 7 (7%) |
| Any PRP treatments in years 3 to 5, N (%) | 31 (10%) | 10 (9%) | 9 (9%) | 12 (11%) |
| Any Focal/grid laser treatments in years 3 to 5, N (%) | 25 (8%) | 12 (10%) | 6 (6%) | 7 (7%) |
Abbreviations: DME = diabetic macular edema; DR = diabetic retinopathy; IQR = interquartile range; PRP = panretinal photocoagulation SD = standard deviation; VEGF = vascular endothelial growth factor.